Nasal congestion

• The Law Offices of Frank R. Cruz announces an investigation of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE ) on behalf of investors concerning the Company’s possible violations of federal securities laws issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering").
• In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
• On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2023, injuring investors.
• This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

• Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR).
• The reduction in nasal symptoms conferred by Bentrio was 2.4 times larger than with saline nasal spray and clinically relevant.
• Additional data, which have become subsequently available from the NASAR trial, confirm and reinforce the body of evidence demonstrating Bentrio’s efficacy in SAR management.
• Further, the read-out from the NASAR trial suggest that Bentrio helps reduce the need for relief medication (cetirizine nasal spray).

• FMXIN002 is an investigational intranasal epinephrine powder spray device that is noninvasive, user-friendly and reliable and could provide timely effective rescue for severe potentially life-threatening allergic reactions to food, medications and insect bites.
• The clinical study provides additional compelling evidence to the robustness of Nasus Pharma's intranasal powder technology already tested in other drugs.
• "The publication of our results in a prominent scientific journal such as JACI: In Practice will ensure the dissemination of FMXIN002's promise within the relevant medical community."
• Yet an additional advantage for powder-based formulation of epinephrine, a drug that undergoes rapid degradation in the currently-available short shelf-life liquid dosage forms.

• Visits to the NHS hay fever advice page have increased by 252% since the beginning of May, signifying the magnitude of the problem.
• Typically associated with spring and early summer, hay fever symptoms appear to have intensified in the UK in recent weeks.
• A number of environmental factors may be contributing to the current hay fever havoc – including thunderstorms, which can exacerbate symptoms for people with allergies as well as asthma.

What about thunderstorms?

• During thunderstorms, a process called pollen fragmentation occurs, where rainwater breaks down pollen granules into smaller particles.
• The process of pollen fragmentation during thunderstorms can also release allergenic proteins, making the pollen particles more potent.
• These factors highlight the complex interplay between environmental triggers, pollen characteristics and respiratory health in relation to hay fever and asthma.
• Understanding these mechanisms can hopefully help us in developing effective strategies for managing and mitigating the effects of these conditions.

How can I manage my hay fever symptoms?

• If you’re struggling with hay fever symptoms, here are a few tips.
• Check the pollen count in your area: This information can be found through the Met Office, local weather forecasts, online pollen trackers, or smartphone apps.
• Similarly, keeping fresh flowers inside the house can introduce additional allergens into the environment, so it’s best to avoid having these indoors during hay fever season.
• They can provide guidance on suitable medications, immunotherapy, or other interventions to help manage your hay fever or asthma effectively.